News

HealthTech is among our four main priority verticals as an investor. It has the power to preserve, transform and improve lives. More than ever it requires innovation, new approaches and bold entrepreneurs to tackle pressing challenges. We are very happy to announce that some of these visionary entrepreneurs pushing HealthTech forward are the founders of Healee, our newest investment together with HR Capital.

Two new companies are joining the #OneOf11 family in April. Without further adieu, let’s take a closer look and ONDO and Eljoy. ONDO (IndigoVerge). Eleven has made an investment in IndigoVerge – a company with 15+ years of experience in developing web and mobile applications serving the IoT and Industrial Automation domain.

That’s right – we’ve got two new companies joining the #OneOf11 family in November and we are pretty stoked about them. As a matter of fact, they are very different from one another – a sustainable fashion marketplace and a data security company. As always the two commonalities they have is the exceptional founding team and the potential for growth.

How can technology enhance our lives, redefining fundamental processes with years of existence in the health area? How close is the mass adoption of technologies like 3D tissue and organ printing? Can the future smart pharmacy recognize, remember, reward and recommend personalized medicines and health services based on data and predictive analytics?

At the end of 2018, we announced the first investments of our second fund. Eight companies, coming from different fields and disrupting various industries. Today we are thrilled to announce that two more companies are joining the #OneOf11 family – fintech startup Payhawk and the indie game development company Rebellious Software.

We are happy to announce the first investments of our second fund. We met, more than 200 startups in the past several months and we are very thrilled with their quality and traction. Choosing the ones to invest in was not an easy task. We passed on a few great teams and projects that were priced higher than our expectations or needed more market validation.